TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00515502

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GSK573719
Description: 250 micrograms (μg) per blister, administered via dry powder inhaler, dose-ascending study doses began at 250 ug, then 500 ug, and 1000 μg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GSK573719
Description: 250 micrograms (μg) per blister, administered via dry powder inhaler, dose-ascending study doses began at 250 ug, then 500 ug, and 1000 μg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GSK573719
Description: 250 micrograms (μg) per blister, administered via dry powder inhaler, dose-ascending study doses began at 250 ug, then 500 ug, and 1000 μg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GSK573719
Description: 250 micrograms (μg) per blister, administered via dry powder inhaler, dose-ascending study doses began at 250 ug, then 500 ug, and 1000 μg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GSK573719
Description: 250 micrograms (μg) per blister, administered via dry powder inhaler, dose-ascending study doses began at 250 ug, then 500 ug, and 1000 μg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium
Description: strips of five capsules, each containing 18 μg administered via dry powder inhaler

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium
Description: strips of five capsules, each containing 18 μg administered via dry powder inhaler

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium
Description: strips of five capsules, each containing 18 μg administered via dry powder inhaler

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium
Description: strips of five capsules, each containing 18 μg administered via dry powder inhaler

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium
Description: strips of five capsules, each containing 18 μg administered via dry powder inhaler

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium
Description: strips of five capsules, each containing 18 μg administered via dry powder inhaler

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium
Description: strips of five capsules, each containing 18 μg administered via dry powder inhaler

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium
Description: strips of five capsules, each containing 18 μg administered via dry powder inhaler
Study: NCT04199949

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Inactivity
Description: On days 1 and 6 of each main trial, the participants will be asked to attend the laboratory after an overnight fast of at least 8 to 12h to undergo brachial and popliteal arteries FMD measurements (30 min apart) using duplex-Doppler ultrasound, followed by assessment of the hand grip strength of their non-dominant hand using a hand dynamometer.
Study: NCT00151242

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: All-trans retinoic acid
Description: 45mg/m² p.o. day 6-8 (induction therapy) 15mg/m² p.o. day 9-21 (induction therapy) 15mg/m² p.o. day 6-21 (consolidation therapy)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegfilgrastim
Description: 6mg s.c day 10 (cohort 1), 6mg s.c. day 8 (cohort 2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: 6mg s.c day 10 (cohort 1), 6mg s.c. day 8 (cohort 2)
Study: NCT00644917

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xenaderm
Description: 20mg under Finn chambers

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 20mg under Finn chambers
Study: NCT02216942

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Endodontic treatment using Vitapex
Description: Endodontic treatment using Vitapex

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endodontic treatment using Guedes Pinto
Description: Endodontic treatment using Guedes Pinto paste
Study: NCT02022384

Intervention type: OTHER
Intervention: Blood sample and life quality questionnaires
Description: Blood will be drawn at distinct time points during and after radio(chemo)therapy
Study: NCT00003441

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irofulven (MGI-114)
Description: IV over 5 minutes daily for 5 consecutive days. Courses repeated every 28 days. Minimum treatment period is 2 courses.
Study: NCT02846155

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: clear water
Description: the patients just drink common clear water before Magnetic-controlled Capsule Endoscopy examination

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: simethicone
Description: the patients drink clear water and simethicone (Espumisan; Berlin-Chemie, Germany, containing 40 mg simethicone in 1 mL emulsion) before Magnetic-controlled Capsule Endoscopy examination

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: simethicone combined with pronase
Description: the patients drink simethicone (Espumisan; Berlin-Chemie, Germany, containing 40 mg simethicone in 1 mL emulsion)，pronase granules（Deyou；Beijing Tide Pharmaceutical Co，China,containing 20,000iu pronase），and clear water before Magnetic-controlled Capsule Endoscopy examination
Study: NCT01059175

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Additional Endocardial or Epicardial LV Lead
Description: Addition of a second left ventricular endocardial or epicardial lead

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CRT-P or CRT-D
Description: Implantable Cardiac Resynchronization Therapy Pacemaker (CRT-P) or Defibrillator (CRT-D) Device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CRT-P or CRT-D
Description: Implantable Cardiac Resynchronization Therapy Pacemaker (CRT-P) or Defibrillator (CRT-D) Device
Study: NCT02040116

Intervention type: DRUG
Group type: OTHER
Intervention: Rituximab Infusion
Description: Participants will receive their first infusion of rituximab at the standard infusion rate provided in the manufacturer labeling. If they tolerate this infusion with a grade 2 of less infusion-related reaction, the next infusion will be administered as a 90 minute rapid infusion.
Study: NCT04385368

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab + SoC chemotherapy
Description: Experimental Treatment

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + SoC chemotherapy
Description: Placebo Comparator
Study: NCT00591474

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: probiotics
Description: 100 gms of a yogurt drink containing probiotics will be given to pVRE positive patients for 4 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: yogurt
Description: 100 gms of pasteurized yogurt drinks with no live cultures will be given to VRE positive patients for 4 weeks
Study: NCT02115633

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Walkasins ON
Description: Subjects will be wearing a device that works as intended and provides real-time vibrotactile feedback that reflects center of pressure sway.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Walkasins ON
Description: Subjects will be wearing a device that works as intended and provides real-time vibrotactile feedback that reflects center of pressure sway.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Walkasins OFF
Description: Subjects will be wearing a device that is turned off.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Walkasins OFF
Description: Subjects will be wearing a device that is turned off.
Study: NCT02732938

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04136309
Description: PF-04136309 oral dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Nab-paclitaxel IV dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine IV dosing
Study: NCT02486484

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ziv-aflibercept
Description: zaltrap injection
Study: NCT04158050

Intervention type: DRUG
Intervention: IL5 Antagonist or anti-IL5R-antibody or Omalizumab
Description: mepolizumab, reslizumab, benralizumab and omalizumab in severe asthma

Intervention type: DRUG
Intervention: IL5 Antagonist or anti-IL5R-antibody or Omalizumab
Description: mepolizumab, reslizumab, benralizumab and omalizumab in severe asthma
Study: NCT01179204

Intervention type: PROCEDURE
Intervention: Preoperative heat stimulation
Description: Preoperative short and long tonic heat stimulation
Study: NCT02281669

Intervention type: DRUG
Intervention: Pentostam
Description: Intralesional injection of Pentostam
Study: NCT02123108

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Basiliximab
Description: Peri-operative 40 mg IV dose within 4 hours of OLT Postoperative 20mg IV dose Day 4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Day #7 post-transplant or when serum creatinine (SCr) \< 1.8 mg/dl 6 months to 1 year: 0.03-0.1 mg.kg q12h po to maintain whole blood trough concentration of 3-5ng/mL

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Day #1 post-transplant to 6 months: 0.03-0.1mg/kg q12h po to maintain whole blood trough concentration of 7-10 ng/mL + 6 months to 1 year: maintain whole blood trough concentration of 5-8ng/mL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolic Acid
Description: Enteric coated mycophenolic acid 360-720 mg po bid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolic Acid
Description: Enteric coated mycophenolic acid 360-720 mg po bid
Study: NCT03833882

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MAF1217
Description: The study population will have to self-administer the study treatment in a TID posology.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MAF1217
Description: The study population will have to self-administer the study treatment in a TID posology.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cationorm
Description: The study population will have to self-administer the study treatment in a TID posology.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cationorm
Description: The study population will have to self-administer the study treatment in a TID posology.
Study: NCT00498719

Intervention type: BEHAVIORAL
Intervention: Cognitive Training Program
Description: Cognitive training sessions over a 4 to 6 month training period, each lasting about 2 hours.

Intervention type: OTHER
Intervention: Control Group
Description: Standard educational support.
Study: NCT04592445

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Satera GSN Ablation
Description: The Axon procedure consists of a small needle puncture made in the groin to pass standard sheaths, wires, and access devices into the femoral vein, using standard access methods. The right GSN will be ablated transvenously from the right intercostal veins where it crosses at the 10th and 11th thoracic vertebrae from the intercostal vein intersection with the azygos vein. Placement of the access devices and Axon catheter is confirmed using standard fluoroscopic imaging. Once positioning is confirmed, GSN ablation can commence accordingly .

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Control
Description: The sham procedure consists of a small needle puncture made in the groin to pass a standard femoral introducer sheath approximately 10 cm into the femoral vein, using standard access methods. The Axon Catheter and associated access accessories will not be inserted into the patient. The sham procedure duration will be similar to the treatment time for subject receiving the Axon therapy (\~30 minutes).
Study: NCT02683850

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 SPM™ softgel
Description: This four week, prospective, non-randomized, open-label study is assessing the impact on quality of life from taking an Omega-3 SPM™ softgel supplement in adults with pain symptoms at screening of 4 or higher on the PROMIS-43 Profile - Pain Intensity subscale.
Study: NCT00676767

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Resistant Starch Type 4

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dextrose

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Puffed wheat
Study: NCT01433354

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AFQ056
Description: The investigational drug, AFQ056, will be provided as hard gelatin capsules. Two different oral dosage strengths,25mg and 100 mg, identical in appearance, will be used.
Study: NCT01952496

Intervention type: OTHER
Group type: OTHER
Intervention: Assisted Standing Treatment Program
Description: Assisted standing treatment program will include at least 2 hours a day, 5 days a week (a total of at least 10 hours a week) for a period of \~9 months.~Arm: Force-measuring platform
Study: NCT00163579

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bryophyllum

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00894231

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levocetirizine (Xyzal)
Description: 5mg po QD

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: sugar tablet
Study: NCT01926730

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Restriction diet
Description: Selected food items will be limited in the participants diet
Study: NCT02781402

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 4 weeks of Aerobic Training
Description: The duration of aerobic training was 40 minutes for each session and 3 days per week with the intensity of 75-80% of their maximum heart rate. The participants were needed to walk or jog on treadmill during the first 10 minutes at the intensity of 50-60% of maximal heart rate (HR max). The aerobic training was followed by 4 x 4 minutes intervals at 75-80% HR max. The participants were given 3 minutes active breaks in between the intervals in which they can either walk or jog at 50-60% of maximal heart rate.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 4 weeks of Aerobic Training
Description: The duration of aerobic training was 40 minutes for each session and 3 days per week with the intensity of 75-80% of their maximum heart rate. The participants were needed to walk or jog on treadmill during the first 10 minutes at the intensity of 50-60% of maximal heart rate (HR max). The aerobic training was followed by 4 x 4 minutes intervals at 75-80% HR max. The participants were given 3 minutes active breaks in between the intervals in which they can either walk or jog at 50-60% of maximal heart rate.
Study: NCT04124926

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vonoprazan
Description: Over-encapsulated tablet administered orally with approximately 240 mL water, 30 minutes prior to the morning meal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vonoprazan
Description: Over-encapsulated tablet administered orally with approximately 240 mL water, 30 minutes prior to the morning meal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vonoprazan
Description: Over-encapsulated tablet administered orally with approximately 240 mL water, 30 minutes prior to the morning meal.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lansoprazole
Description: Over-encapsulated capsule administered orally with approximately 240 mL water, 30 minutes prior to the morning meal.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lansoprazole
Description: Over-encapsulated capsule administered orally with approximately 240 mL water, 30 minutes prior to the morning meal.
Study: NCT01487811

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart 30
Description: Single dose administrated subcutaneously (s.c., under the skin)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: biphasic insulin aspart 30
Description: Single dose administrated subcutaneously (s.c., under the skin)
Study: NCT00338884

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib malate
Description: Sunitinib malate starting dose 37.5 mg daily continuous daily schedule
Study: NCT02374905

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Drinksmeter
Description: Web-based application delivering Identification and Brief Advice of Alcohol Use

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief Advice of Alcohol Use
Description: Lifestyle counseling regarding alcohol intake and completion of Audit-10 questionnaire done chair-side with clinician
Study: NCT02724163

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: A water-soluble fluorinated nucleotide analogue of the antiviral agent vidarabine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Pyrimidine nucleoside analogue, an antineoplastic agent.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytarabine
Description: Pyrimidine nucleoside analogue, an antineoplastic agent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Pyrimidine nucleoside analogue, an antineoplastic agent.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytarabine
Description: Pyrimidine nucleoside analogue, an antineoplastic agent.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Busulfan
Description: Alkylsulfonate
Study: NCT02374905

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Advice of Alcohol Use
Description: Lifestyle counseling regarding alcohol intake and completion of Audit-10 questionnaire done chair-side with clinician
Study: NCT02724163

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Alkylsulfonate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: A nitrogen mustard alkylating agent from the oxazaphosphorine group
Study: NCT01289639

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fenofibrate
Description: micronized fenofibrate 200 mg 1 po qd
Study: NCT03219476

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: 1 mg once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: 2.5mg once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: 25 mg once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Description: 20 mg once daily.
Study: NCT04284774

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration and Biopsy
Description: Undergo bone marrow aspiration or biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo a CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo a PET scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radionuclide Imaging
Description: Undergo a MIBG scintigraphy scan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tipifarnib
Description: Given PO or via nasogastric or gastric tube
Study: NCT03549299

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LSC2
Description: Topical application of IMP on target eye

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LSC2
Description: Topical application of IMP on target eye

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LSC2
Description: Topical application of IMP on target eye

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LSC2
Description: Topical application of IMP on target eye
Study: NCT03158818

Intervention type: OTHER
Intervention: Standard of care
Description: Routine standard of care per Ministry of Health protocol, including blood draws and examinations.
Study: NCT02081196

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Zeltiq CoolSculpting System
Description: Non-invasive cooling is applied to the treatment area with a defined cooling rate and duration.
Study: NCT01961453

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isosorbide Mononitrate, sustained release
Description: 60 mg if Titration Stage 1 OR 120 mg if Titration Stage 2

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsule
Description: One capsule of placebo administered once daily at 8 am.
Study: NCT01100268

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate ER
Description: Subjects will start at 18mg/day; the dose will be increased in increments of 18mg per week to reach 72mg/day.
Study: NCT03154827

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BL-8040
Description: Subjects will receive maintenance treatment consisting of subcutaneous (SC) injections of BL-8040 on Days 1, 2 and 3 of each 21-day cycle. Cycles will be repeated for up to 2 years (a maximum of 34 treatment cycles), until early discontinuation for any reason or until disease relapse, whichever comes first.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Subjects will receive maintenance treatment consisting of intravenous (IV) infusion of Atezolizumab on Day 2 of each 21-day cycle. Cycles will be repeated for up to 2 years (a maximum of 34 treatment cycles), until early discontinuation for any reason or until disease relapse, whichever comes first.
Study: NCT04991623

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kinesiology taping
Description: We used kinesiology taping in abdominal muscles

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional physiotherapy
Description: We used conventional physiotherapy to comparate
Study: NCT04133233

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ILT101
Description: Treatment administration consists in a first course of five-day treatment (induction), followed by a single injection every week for 4 weeks (maintenance; from Week 3 to Week 6)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Treatment administration consists in a first course of five-day treatment (induction), followed by a single injection every week for 4 weeks (maintenance; from Week 3 to Week 6)
Study: NCT02013622

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brexpiprazole
Description: Treatment (16 weeks) Up to 4 mg/day, once daily dose, tablets, orally
Study: NCT01889433

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Algeron
Description: 1.5 µg/kg of body weight subcutaneously, once a week

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegasys
Description: 180 µg subcutaneously, once a week
Study: NCT03552874

Intervention type: OTHER
Intervention: The Performance of Upper Limb Questionnaire (PUL)

Intervention type: OTHER
Intervention: The Performance of Upper Limb Questionnaire (PUL)
Study: NCT03806270

Intervention type: DRUG
Intervention: Midazolam
Description: Demizolam 15mg/ml ampules, given orally with cherry juice